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ABSTRACT
There are only few reports on protein products
originating from overlapping mammalian genes
even though computational predictions suggest
that an appreciable fraction of mammalian genes
could potentially overlap. Mass spectrometry-based
proteomics has now acquired the tools to probe
proteins in an unbiased manner, providing direct
evidence of the output of the genomic and gene ex-
pression machinery. In particular, proteomics can
refine gene predictions and discover novel gene-
processing events and gene arrangements. Here,
we report the mass spectrometric discovery and
biochemical validation of the novel protein
encoded by a gene overlapping rab34 oncogene.
The novel protein is highly conserved in mammals.
In humans, it contains 13 distinct Nine-Amino acid
Residue-Repeats (NARR) with the consensus
sequence PRVIV(S/T)PR in which the serine or
threonine residues are phosphorylated during
M-phase. NARR is ubiquitously expressed and
resides in nucleoli where it colocalizes with riboso-
mal DNA (rDNA) gene clusters. Its distribution only
partially overlaps with upstream binding factor, one
of the main regulators of RNA Polymerase I activity,
and is entirely uncoupled from it in mitotic cells and
upon inhibition of transcription. NARR only partially
colocalizes with fibrillarin, the pre-ribosomal
RNA-processing protein, positioning NARR in a
separate niche within the rDNA cluster.
INTRODUCTION
Mass spectrometry-based proteomics has become an
indispensable protein identiﬁcation and characterization
tool (1), which provides efﬁcient means to link genomic
predictions with bona ﬁde proteomes. Typically, prote-
omics data are queried against databases of known
proteins. Even though a signiﬁcant portion of the
spectrum queries remains unassigned to peptide
sequences, these data are not routinely searched against
genomic or EST expressed sequence tags (EST) databases
(2). This is mainly due to processing constraints; transla-
tion in six frames creates databases of a size signiﬁcantly
larger than that of the conventional protein databases.
Furthermore, the statistical challenges to unambiguously
assign peptides to the genome require excellent data
quality in order to avoid high false positive rates.
Nevertheless, it is obvious that such unassigned mass
spectrometric data may contain unique information
about the output of the gene expression machinery that
could provide key data to answer many genomic puzzles.
Thus, proteomics can partially validate gene predictions
and discover novel difﬁcult to predict genes, gene-
processing events and gene arrangements. Our labora-
tory has previously reported the MS-based discovery
of new genes (3) as well as evidence for unsuspected
RNA editing events leading to different protein
isoforms (4).
The nucleolus is a conserved subnuclear compartment
with key functions in synthesis and processing of riboso-
mal RNAs as well as many other cellular functions (5). It
is the place where the initial steps of ribosome subunit
assembly occur. The nucleolus is formed around clusters
of repeated rRNA genes (rDNA) that encode ribosomal
RNA (rRNA), the scaffold and catalytic heart of the
eukaryotic ribosome (6). In humans, the clusters of
rDNA repeats, called nucleolar organizer regions
(NORs), are positioned on the short arms of the
acrocentric chromosomes 3, 14, 15, 21 and 22. Extensive
proteomic studies have provided insights into the nucle-
olar protein composition (7–9) and of its dynamics
(10,11). These studies have supported the notion of the
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the dynamics of proteins involved in cell cycle control,
stress response and synchronization of biogenesis.
Here, we describe the discovery of a novel nucleolar
protein Nine-Amino acid Residue-Repeats (NARR),
which arises from the transcription of a gene overlapping
the rab34 oncogene. The protein was identiﬁed by
analyzing unassigned shotgun proteomics data, veriﬁed
extensively by high-resolution MS as well as by
immunochemical methods. NARR is one of the very few
documented examples of protein products of overlapping
genes in humans.
MATERIAL AND METHODS
Cell culture
Human MCF7 and HeLa cells were cultured in dubelcco’s
modiﬁed eagle medium (DMEM) (GIBCO) supplemented
with 10% fetal bovine serum (FBS) and 1% penicillin/
streptomycin. For stable isotope labelling with amino
acids in cell culture (SILAC) experiments, MCF7 cells
were cultured with either normal or stable isotope
labeled (
13C6
15N2) lysine and (
13C6
15N4) arginine (12).
For immunoﬂuorescence (IF) experiments, cells were
grown either on ‘BD-BioCoat’ collagen-coated coverslips
(BD Biosciences) or on microscope slides (Superfrost Ultra
Plus, Thermo Scientiﬁc). When required, MCF7 cells were
treated with 100ng/ml of actinomycin D (ActD) for 14h.
Extraction of proteins from cells and nuclei
Nuclei were isolated by differential pelleting of MCF7 cell
homogenates. Brieﬂy, fresh cells were homogenized in a
tight-ﬁtted Potter-Elvehjem homogenizer (Sartorius) in
phosphate buffered saline (PBS) containing Protease
Inhibitor Cocktail (Roche Diagnostics) at 4 C. Cell
debris was removed by centrifugation at 100g for 5min
and then the nuclei were collected at 800g for 10min.
Proteins were extracted from whole cell pellets or from
nuclei by three freezing ( 20 C), thawing and vortexing
(10s) cycles in 0.2M HCl and were precipitated with 25%
(w/v) CF3COOH, washed twice with 0.2% (v/v) HCl in
acetone and once with pure acetone and vacuum dried.
Whole SDS lysates of cultured cells and mouse tissues
were prepared as described previously (13).
For pull-down experiments, the nuclei of MCF7 cells
were extracted with 0.6M NaCl in 20mM Tris–HCl, pH
7.6, containing ethylene diamine tetraacetic acid
(EDTA)-free Roche Protease Inhibitor Cocktail. The
extracts were diluted eight times with PBS and clariﬁed
by centrifugation at 15000g for 10min.
Antibody production
Antibodies against NARR were raised in rabbits using
a synthetic peptide C-RQDEHSGTRAEGSR conjugated
to ‘Imject Maleimide Activated Ovalbumin’ (Pierce).
Animals were injected with 0.2mg of the cross-linked
peptide. Titer and speciﬁcity of the antisera was increased
by three injections (boosts).
Mono-speciﬁc antibodies were puriﬁed on afﬁnity
columns prepared by coupling of the peptide to
iodoacetate-activated gel (SulfoLink, Pierce) according
to the manufacturer’s protocol using 1mg of the peptide
per 1ml of the coupling gel. The unreacted maleimide
groups were quenched with 20mM cysteine. Afterward,
1ml of the resin was loaded onto a column and washed
with 50ml PBS. Five milliliters of the antiserum was
diluted with 10ml PBS and incubated with the resin for
4h. After washing with 50ml PBS, the bound antibodies
were eluted with 10ml of 0.1M glycine–HCl, pH 2.5, and
the eluates were diluted with 10ml of PBS and
concentrated in Centriprep-Ultracel YM-10 (Millipore)
concentrators to a volume of 2ml. The concentrates
were dialyzed against PBS overnight and stored frozen
in 50% glycerol.
Production of recombinant NARR
Partially puriﬁed NARR protein was produced in the
Core Facility of the MPI of Biochemistry using the
Escherichia coli BL21 expression system. NARR gene
with its codons optimized for expression in E. coli was
synthesized by GenScript. The gene was inserted into
a modiﬁed version of the EMBL pETM vector
pETM44-ccdB (N-HIS-MBP) using the SLIC cloning
method (14). Speciﬁc elution from the Ni-Sepharose
(GE HealthCare) beads was achieved by incubation with
PreScission Protease (GE HealthCare), and subsequently
protein products were puriﬁed by gel-ﬁltration on HiLoad
26/60 Superdex 200 column (GE HealthCare).
Western blotting
For western analysis, proteins were transferred from
sodium dodecylsulfate (SDS) gels onto the nitrocellulose
membrane by electroblotting at 10V/cm for 40min. The
proteins were cross-linked to the membrane by incubation
in 0.5% (v/v) glutaraldehyde in PBS for 10min. The mem-
branes were blocked with 10% (v/v) normal goat serum
(NGS) for 30min prior to incubation with the primary
antibodies together with 1% NGS in PBS containing
0.1% Tween 20 (PBS-T). Following 2-h incubation, the
membrane was extensively washed with PBS-T. Primary
antibodies were visualized on the membrane with
peroxidase-conjugated immunoglobulins. After the detec-
tion of antibodies, blots were stained with Amido Black
stain (Sigma, St Louis, MO, USA). The anti-NARR
antibodies (concentration 1.0mg/ml) were used in 1:4000
dilution. The following commercial antibodies were
used—mouse anti-EIF5A (BD Biosciences, 611976),
mouse anti-UBF (Abnova, H00007343-M01) and rabbit
anti-ERF1 (Sigma, E8156)—all in 1:1000 dilutions.
Indirect IF
MCF7 cells were ﬁxed with 4% paraformaldehyde in PBS
for 15min and permeabilized with 0.2% Triton X-100 in
PBS for 20min. Non-speciﬁc binding was blocked by
incubation in 10% (v/v) NGS. The monoclonal mouse
anti-EIF5A (BD Biosciences, 611976), anti-UBF
(Abnova, H00007343-M01) and anti-ﬁbrillarin antibodies
(Genetex, GTX24566) were used in a 1:500, 1:1000 and
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used in 1:500 dilution. Antibodies were visualized using
secondary antibodies conjugated to AlexaFluor dyes 488
or 594 (Invitrogen) in 1:700 dilution. Nuclei were counter-
stained with 40,6-diamidino-2-phenylindole (DAPI).
Coverslips were mounted with MobiGLOW (Mobitec)
mounting medium. Analyses were performed using
LEICA TCS SP2 and Zeiss Axioplan 2 imaging systems.
Combined ﬂuorescence in situ hybridization and IF
The procedure was performed as per guidelines outlined
previously (15) with minor modiﬁcations as follows.
MCF7 cells were grown on microscope slides (Superfrost
Ultra Plus, Thermo Scientiﬁc), washed with PBS and ﬁxed
with 4% paraformaldehyde in PBS for 20min. The cells
were permeabilized for 25min with 0.25% Triton X-100 in
PBS followed by 0.5% Saponin in PBS for 10min.
Afterwards, the slides were depurinated in 0.1N HCl for
10min. For denaturation, the slides were placed in 70%
formamide/2  saline-sodium citrate (SSC) for 3min at
74 C followed by 1min in 50% formamide/2  SSC at
74 C. Acrocentric chromosome p arms red ﬂuorophore
probe (LPE NOR Aquarius probe, Cytocell), 25ng per
slide, was denatured separately for 2min at 74 C.
Subsequently, the probe was applied to the slide,
covered with a coverslip, sealed with a Fixogum rubber
solution which was then allowed to dry. After that, the
sample and the probe were heated at 74 C for 2min and
incubation was performed for 16h in a humidiﬁed
chamber at 37 C. Following the incubation, the coverslip
was removed and the slides were washed in 0.4  SSC at
72 C for 2min, and then with 2xSSC at room temperature
(RT) for 2min, followed by three washes in PBS for 2min
at RT. Indirect IF staining was performed as described
above using 1:300 dilution of the anti-NARR primary
antibody. The primary antibody was visualized using
1:500 dilution of the secondary antibody conjugated to
AlexaFluor 488 dye (Invitrogen). The nuclei were coun-
terstained with DAPI. Coverslips were mounted with
FluorPreserve (Calbiochem) mounting medium. The
Zeiss Axioplan 2 system was used for image acquisition.
Pull-down experiments
The peptide CSPRPRNARRGTIRPRNARRGTIRPR
NARRGSARAR comprising three NARR repeats and
carrying N-terminal cysteine for coupling was synthesized
in-house by solid phase synthesis. The peptide was
coupled to SulfoLink gel (Pierce) according to the manu-
facturer’s protocol. SulfoLink gel blocked with cysteine
was utilized as a control column.
For SILAC-based pull downs, MCF7 nuclear extracts
from either ‘light’ or ‘heavy’-labeled cells were applied to
the counterpart (control and peptide-bound) columns
(16). The columns were washed with PBS. Elution was
performed with 0.1M glycine–HCl buffer, pH 2.2. The
eluates from the control and peptide-bound columns
were mixed and analyzed by liquid chromatography
tandem mass spectrometry (LC-MS/MS).
For western blotting, MCF7 nuclear extracts were
applied to the peptide-coupled and control columns.
The columns were washed with PBS and elution was
performed in two steps—ﬁrst, with 1mM solution of
NARR peptide and, secondly, with 2% SDS.
Identiﬁcation of phosphorylation sites
HeLa cells at 80% conﬂuence were treated with 0.1mg/ml
nocodazole for 16h and then harvested and extracted with
0.2N HCl (as described above). Proteins were precipitated
with 25% (w/v) CF3COOH as described previously (17)
and the pellets were dissolved in 2% (w/v) SDS, Tris–HCl,
pH 8.0. The proteins were digested with trypsin according
to the ﬁlter aided sample preparation (FASP) procedure
(13) using an Amicon Ultra 15 Ultracel 30k (Millipore)
device as described previously (18). Five milligrams of
tryptic peptides was acidiﬁed with CF3COOH and
phosphopeptides were enriched on 10mg TiO2-beads ac-
cording to ref. (19) with minor modiﬁcations (18). The
phosphopeptide-enriched fractions were vacuum-dried
and fractionated into six fractions using a pipette-based
SAX column (20).
LC-MS/MS analysis
Proteins were separated by SDS–PAGE. In-gel protein
tryptic digestion was performed as described (21), the
peptide mixtures were desalted using in-house made C18
StageTips (22), vacuum-dried and reconstituted in 0.5%
acetic acid prior to analysis. The LC-MS/MS analytical
setup was similar to that described before (4). Brieﬂy, the
samples were injected onto an in-house made 15cm
capillary emitter column [inner diameter 75mm, packed
with 3mm ReproSil-Pur C18-AQ media (Dr Maisch
GmbH, Ammerbuch-Entringen, Germany)], using a
Proxeon EASY-nLC system (Proxeon Biosystems,
Odense, Denmark, now Thermo Fisher Scientiﬁc). The
LC setup was connected to an LTQ Orbitrap mass spec-
trometer equipped with a nanoelectrospray ion source
(Proxeon Biosystems). The peptide mixtures were
separated with gradients from 5% to 40% CH3CN in
0.5% acetic acid. Data-dependent acquisition was
employed. MS spectra were acquired in the Orbitrap
analyzer with the resolution of 60000 (at m/z of 400);
MS/MS spectra were acquired in the ion trap. Data
analysis was performed with the MaxQuant software (23).
The nominal m/z (391) of the N-terminal doubly-
charged VGQPQPR tryptic product of NARR coincides
with the m/z of one of the most common MS contamin-
ants, dioctyl phthalate, in its singly-protonated form. This
fact complicated identiﬁcation of the N-terminal peptide
of NARR. However, this peptide was nevertheless
identiﬁed in the SILAC-labeled cell lines due to the mass
shift introduced by ‘heavy’ arginine, leading to a mass
devoid of interference by dioctyl phthalate.
RESULTS
Analysis of unassigned MS data reveals a novel protein
In the course of our proteomic work on the nucleus, we
employed a biochemical protein extraction method aimed
at small nuclear proteins. This procedure employs
Nucleic Acids Research, 2011,Vol.39, No. 16 7105extraction with diluted acids, which is a commonly used
technique for isolation of highly charged nuclear proteins.
In this workﬂow, early denaturation inhibits protein
degradation and loss of post-translational modiﬁcations,
such as phosphorylation, acetylation or methylation. It is
not only a standard method for the isolation of histones
and high-mobility group proteins (24), but also is very
useful for the analysis of many other similar protein
classes (17,25). A high resolution MS-based proteomics
analysis of proteins extracted with 0.2N HCl from
isolated MFC7 nuclei led to the identiﬁcation of
hundreds of proteins (data not shown); however,
a portion of the MS/MS data remained unassigned to
any known protein in the International Protein Index
database. With a view to identify potential novel
proteins, we then searched the unassigned data against
a human EST database (see ‘Materials and Methods’
section). This revealed 10 peptides matching the EST
CX872465 that completely covers the mRNA sequence
of a so far undiscovered 198 amino acid residue proteins
(Figure 1A; Supplementary Figure S1; Table 1). Peptide
masses were measured with low to subparts per million
(ppm) mass accuracy and the number of peptides
matched to this small protein implies completely unam-
biguous protein identiﬁcation (65% percent sequence
coverage). The sequence deﬁnes a novel gene which
overlaps rab34 gene on chromosome 17 at q11.2. The
transcript sequence revealed by the EST shows that the
coding sequence of the protein overlaps the ﬁrst 3 of the
10 exons of rab34. The alternative translation start site is
located upstream of the rab34 start codon (Figure 1B;
Supplementary Figure S2) and the complete coding
sequence of NARR is contained in rab34 gene. The MS
data veriﬁed the N-terminus of the protein independently
of the transcript data by direct sequence information
of the N-terminal peptide of the protein (Table 1).
The novel protein contains multiple copies of a nine
amino acid residue repeat
Based on its amino acid sequence, the novel 198 residue
protein is highly basic (pI 12.2), rich in proline (18.2%)
and arginine (17.2%) but does not contain any lysines.
Analysis of the primary structure revealed the presence
of 13 Nine Amino acid Residue Repeats and therefore
we named the protein ‘NARR’ (Figure 2A). Each repeat
is ﬂanked on both sides by a PR dipeptide, contains
a hydrophobic core with consensus sequence VIVG and
nests at S/T phosphorylation site (Figure 2B). The repeats
constitute 2/3 of the N-terminal portion of the protein
while the C-terminal portion does not possess any
obvious structural signatures. Secondary structure
analysis predicts the protein to be unstructured.
The occurrence of NARR is restricted to mammals. The
protein is highly conserved across species (Figure 2A) with
Table 1. Peptides of the NARR protein identiﬁed by LC-MS/MS
Residues Sequence Modiﬁcation
a Theoretical mass Observed mass Mass deviation (ppm)
1–7 VGQPQPR
h – 790.4325 790.4329  0.50
8–16 DDVGSPRPR pS-12 1077.4604 1077.4600 0.37
17–34 VIVGTIRPR – 1009.6396 1009.6381 1.48
64–70 VIFGTPR – 788.4545 788.4577  4.05
64–70 VIFGTPR pT-68 868.4208 868.4212  0.46
73–79 VILGSPR – 740.4545 740.4541 0.54
73–81 VILGSPRPR – 993.6083 993.6114  3.12
73–81 VILGSPRPR pS-77 1073.5747 1073.5745 0.19
82–97 VIVSSPWPAVVVASPR – 1662.9457 1662.9474  1.02
82–99 VIVSSPWPAVVVASPRPR pS-86; pS-95 2076.0323 2076.0325  0.09
100–108 TPVGSPWPR – 995.5189 995.5169 2.01
118–124 VIVGSPR pS-122 806.4052 806.4046 0.74
127–144 VADADPASAPSQGALQGR – 1709.8333 1709.8357  1.40
154–171 AEGSRPGGAAPVPEEGGR – 1692.8179 1692.8136 2.54
186–192 LPGAPDR 724.3868 724.3847 2.90
aThe phosphorylated peptides were identiﬁed only in cells treated with nocodazole; R
h - heavy-labeled arginine
NARR
RAB 34
atggtagggcagcctcagccccgagatgacgtcgggtctccgcggccccgggttattgta      
M  V  G  Q  P  Q  P  R  D  D  V  G  S  P  R  P  R  V  I  V 
ggaaccatccggccccgcgtaatcgtaggaactatccggccccgcgtaatcgtagggtct 
G  T  I  R  P  R  V  I  V  G  T  I  R  P  R  V  I  V  G  S 
gcgcgggcccggcccccaccagacgggactccccgcccccaattggcggccgaagagtct 
A  R  A  R  P  P  P  D  G  T  P  R  P  Q  L  A  A  E  E  S 
cctcgccccagagtcatcttcgggacgcccagggcccgggtgattttgggctcgccgcgg 
P  R  P  R  V  I  F  G  T  P  R  A  R  V  I  L  G  S  P  R 
ccccgggtgattgtttcatctccgtggcccgcggtggtcgtagcgtctccgagaccgcgg 
P  R  V  I  V  S  S  P  W  P  A  V  V  V  A  S  P  R  P  R 
actcccgtagggtccccgtggccccgagttgtagtcgggacaccccggccgcgggtgatc 
T  P  V  G  S  P  W  P  R  V  V  V  G  T  P  R  P  R  V  I 
gtcgggtctccacgcgcccgggtcgctgacgcggatccggcctcggcgccttctcagggc 
V  G  S  P  R  A  R  V  A  D  A  D  P  A  S  A  P  S  Q  G 
gccctgcaaggccgcaggcaggatgaacattctggcacccgtgcggagggatcgcgtcct 
A  L  Q  G  R  R  Q  D  E  H  S  G  T  R  A  E  G  S  R  P 
ggcggagctgccccagtgcctgaggaaggaggccgctttgcacgggcacaaagacttcca 
G  G  A  A  P  V  P  E  E  G  G  R  F  A  R  A  Q  R  L  P 
cccccgcgtcacctgcgcctgccaggagcaccggacaggcaccgtgggcagatttaagat
P  P  R  H  L  R  L  P  G  A  P  D  R  H  R  G  Q  I  -D  
ctccaaggtcattgtggtgggggacctgtcggtggggaagacttgcctcattaatag 
L   Q  G  H  C  G  G  G  P  V  G  G  E  D  L  P  H  --
MVGQPQPRDDVGSPRPRVIVGTIRPRVIVGTIRPRVIVGSARARPPPD
GTPRPQLAAEESPRPRVIFGTPRARVILGSPRPRVIVSSPWPAVVVAS
PRPRTPVGSPWPRVVVGTPRPRVIVGSPRARVADADPASAPSQGALQG
RRQDEHSGTRAEGSRPGGAAPVPEEGGRFARAQRLPPPRHLRLPGAPD
RHRGQI 65% sequence coverage
B
A
Figure 1. (A) Mass spectrometric identiﬁcation of peptides matching
the NARR sequence. Identiﬁed sequence (bold) covers 65% of the pre-
dicted protein primary structure. Experimentally identiﬁed phosphoryl-
ation sites are underlined (B) Genomic structure of the narr and rab34
genes. Start of narr transcription is from the same exon as rab34. The
narr start codon is located 443 base pairs upstream of the rab34 start.
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comprises 13 repeats and predicted NARR proteins in
other mammals have only 12 repeats (Figure 2A). The
repeat phosphorylation site matches the consensus
sequence of cyclin-dependent kinase 1 (CDK1). CDK1 is
particularly active during mitosis and is a regulator of cell
cycle and transcription (26). Since in normally growing
cell culture only a few percent of cells undergo mitosis
at any given time, we did not identify phosphorylation
of NARRs in untreated cells. To speciﬁcally probe for
phosphorylation of the protein during the cell cycle,
we arrested cells in mitosis using nocodazole. After enrich-
ment of phosphopeptides, we identiﬁed six phosphoryl-
ation sites—all localized to the CDK1 consensus sites in
the repeats (Figure 2; Supplementary Figure S3; Table 1).
NARR protein is expressed ubiquitously and localizes
to nucleoli
To further characterize the NARR protein, we raised
antisera in rabbits against the peptide residues 146–159
and afﬁnity puriﬁed the antibodies. The antibody speciﬁ-
city was tested on western blots. We found that the
antibodies strongly and speciﬁcally reacted with the
bacterially expressed NARR protein and the endogenous
protein in whole cell lysates (Figure 3A). Fractionation of
cells into nuclei and cytoplasm revealed that NARR
localizes to nuclei and is absent from the cytosol
(Figure 3B and C). The protein is extractable from
isolated nuclei with 0.8M salt.
To shed some light on the expression of NARR in
different tissues, we prepared whole lysates from ﬁve
mouse organs. We found the single band of NARR in
all lysates (Figure 3D and E), indicating that the protein
is ubiquitously expressed in these tissues. Finally, by IF
analysis we found that NARR localizes to nucleoli. The
speckled appearance suggested NARR’s possible
association with speciﬁc nucleolar complexes
(Figure 3F–H).
NARR and UBF have dissimilar localization signatures
The distinctive nucleolar distribution pattern of NARR
raised the question of colocalization with upstream
binding factor (UBF) and associated proteins (27). UBF
protein binds to the control elements of the rRNA
promoter and is a crucial component of the RNA
polymerase Pol I complex (28,29) participating in
Figure 2. Primary structure of NARR. (A) Multiple alignment of NARR sequences. NAR repeats are boxed in blue. Sequence of the peptide used
for antibody production is underlined. (B) WebLOGO analysis of human and mouse NARRs. S/T residues in position 7 are phosphorylated.
Nucleic Acids Research, 2011,Vol.39, No. 16 7107pre-ribosomal RNA (pre-rRNA) production. Our analysis
showed that NARR and UBF only partially colocalize
during interphase (Figure 4A). In mitotic cells, NARR
seems to disappear or disperse, whereas UBF localizes in
distinct areas (Figure 4B). Actinomycin D (ActD), a
potent inhibitor of rRNA production, causes segregation
of different nucleolar regions. Upon treatment with ActD,
UBF is known to migrate to the nucleolar caps (27). It
turned out that NARR does not follow the UBF path into
the nucleolar caps after the ActD treatment (Figure 4C).
The results suggest that NARR disengages from the
UBF-associated machinery upon inhibition of rDNA
transcription.
NARR only partially colocalizes with ﬁbrillarin
UBF is known to reside both in the nucleolar ﬁbrillar (FC)
and dense ﬁbrillar (DFC) centers. The transcription of the
rRNA genes by RNA polymerase I is believed to take
B C
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A
Figure 3. Occurrence of NARR in human cells and mouse tissues. Western blot of the partially puriﬁed and truncated recombinant NARR (lane 1)
and of whole MCF7 lysate (lane 2) using polyclonal anti-NARR antibody (A). Whole HeLa cell lysates (1), their nuclear extracts (2,3) and cytosol
were separated on SDS–PAGE (B), blotted to nitrocellulose, and probed with polyclonal anti-NARR antibody (C). Whole lysates of mouse tissues
were separated on SDS-PAGE (D), blotted to nitrocellulose, and probed with polyclonal anti-NARR antibody (E). (F–H) Indirect IF confocal
microscopy images of HeLa cells probed with anti-NARR antibodies (F), DAPI staining (G), merged F and G (H).
7108 Nucleic Acids Research, 2011,Vol.39, No. 16place either in DFC or on the border between FC and
DFC (30). While trying to correctly position NARR
within nucleolus, we used antibodies against ﬁbrillarin,
the RNA-20O-methyltransferase present solely in the
dense ﬁbrillar centers of nucleolus. Our analysis shows
only partial colocalization of NARR with ﬁbrillarin in
interphase cells (Figure 4D), suggesting that NARR may
occupy a special niche near the rDNA areas.
DAPI
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DAPI
DAPI
NARR
NARR
NARR
NARR
UBF Overlay
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E
Figure 4. Indirect IF confocal microscopy images of MCF7 cells probed with anti-NARR, anti-UBF, anti-ﬁbrillarin and anti-EIF5A antibodies.
Visualization is with Alexa-488 (NARR, green) and Alexa-594 (UBF, ﬁbrillarin and EIF5A, red)-coupled secondary antibodies (A–F). (A) In
interphase, NARR only partially colocalizes with UBF in nucleoli; (B) in mitosis, NARR disappears or disperses, whereas UBF is restricted to
distinct areas; (C) upon ActD treatment UBF moves to the nucleolar caps but NARR’s localization pattern is unaffected; (D) NARR only partially
colocalizes with ﬁbrillarin in interphase nucleoli; (E) in interphase NARR and rDNA clusters colocalize; visualization in (E) is with combined FISH
(LPE NOR probe, red) and IF (anti-NARR primary, Alexa-488 secondary antibodies, green); (F) EIF5A is visible both in the cytoplasm and
nucleus; in the nucleus EIF5A is concentrated in nucleoli where it is diffusely distributed.
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Because it is known that UBF only associates with
active rDNA clusters in NORs (6), the sites of rRNA
transcription, our ﬁndings suggested that NARR localiza-
tion may be linked to rDNA. Combined ﬂuorescence in
situ hybridization (FISH) and immunoﬂuorescence assay
(immuno-FISH) was performed using a probe against
acrocentric chromosome p arms and anti-NARR
antibody. This showed that NARR and rDNA clusters
indeed colocalize in interphase cells (Figure 4E) providing
evidence for NARR’s association with NORs.
NARR interacts with eukaryotic translation initiation
factor 5A and ERF1
The presence of NARR repeats is a striking unique
property of the protein and we hypothesized that the
repeats may constitute protein interaction sites. To
identify interacting proteins, we performed SILAC-based
pull-down experiments (31,32) using a synthetic
bait-peptide representing a fragment of NARR (residues
13–45) containing three repeats (Figure 5A). The conse-
quent analysis highlighted two proteins, ERF1 and
EFI5A, as potentially interesting NARR interactors
Figure 5. SILAC-based pull-down experiments with immobilized peptide containing three NARR repeats. (A) Sequence of the peptide used for
the pulldown. (B) ERF1 and (C) EIF5A were found with SILAC ratios indicating speciﬁc binding. Representative spectra of EIF5A, ERF1 and UBF
peptides obtained by the SILAC-based proﬁling are shown in corresponding boxes. Asterisks and diamonds indicate relative amount of proteins
bound to the NARR-peptide column and control column, respectively. The interactions were conﬁrmed by western blotting. (D) UBF does not
speciﬁcally interact with the NARR peptide. (E) Boxplot of the results of the SILAC-based pull-down experiment indicates the interactions of EIF5A
and ERF1 with the NARR peptide.
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ratios greater than three and are also present in the nucle-
olar proteome database (7). To verify these interactions,
we analyzed the eluates from NARR peptide and control
by western blotting using antibodies against these proteins
(inserts in Figure 5B and C). Indeed, this experiment
showed that ERF1 and EIF5A were bound only to the
NARR peptide column and that they were speciﬁcally
eluted with the free NARR peptide but not with the
control. Conversely, UBF did not show a signiﬁcant
SILAC ratio and western blots also indicated non-speciﬁc
binding nature of UBF to the NARR peptide column
(Figure 5D).
Although its name suggests a speciﬁc role in translation,
published reports of functional roles of eukaryotic trans-
lation initiation factor 5A (EIF5A) are ambiguous (33).
This ubiquitously expressed protein contains a nuclear
localization signal (34) and is the only protein shown
to carry hypusine—the post-translationally modiﬁed
lysine residue, N(epsilon)-(4-amino-2-hydroxy-butyl)ly-
sine. This modiﬁcation was found to be essential for cell
viability (35,36). Interestingly, EIF5A is known to be
associated with HIV-I Rev protein which partly resides
in nucleoli and orchestrates the export of the viral
mRNAs out of the nucleus (37). Unlike the ERF1
antibody which functioned only in western blotting, the
EIF5A antibody proved to work successfully both for
western blotting and IF. We used it to probe EIF5A
cellular distribution in MCF7 cells and found that even
though EIF5A is detected both in cytoplasmic and nuclear
cellular compartments, in the nucleus it is concentrated in
the nucleolar regions (Figure 4F). This link to nucleolar
processes may be a clue to the essential role EIF5A plays
in cell viability.
DISCUSSION
Correct identiﬁcation of translational start sites is vital
for understanding of protein structure, function and tran-
scriptional regulation. Until recently, the most accepted
‘scanning’ hypothesis of translational site initiation in
eukaryotic mRNAs suggested that proximity to the
50 mRNA end plays a dominant role in identifying the
start codon. This ‘position effect’ becomes apparent in
cases where a mutation creates the AUG codon
upstream of the normal start site of translation (38).
Such a monocistronic model (one mRNA–one protein)
has recently come under scrutiny and, nowadays it is
acknowledged that an mRNA molecule can carry
multiple sites of translation recognizable by the ribosomal
machinery (39). It has also been suggested that the diver-
sity of translation start sites may deﬁne increased com-
plexity of the human short ORFeome (40).
The annotated translational start sites contained in
genome databases are often predicted using bioinformat-
ics and rarely veriﬁed experimentally, and hence it is not
known how accurate they are (41). In general, computa-
tional gene predictions can have high false positive rates
and in principle require experimental veriﬁcation as they
do not by themselves establish that a predicted gene is
deﬁnitely going to be translated into a protein (42).
Proteomics identiﬁes protein products of the genes and
therefore reports on the ﬁnal output of the translation
machinery. Hence, in addition to conﬁrming predicted
genes, proteomics can supply unique information poten-
tially leading to discovery of novel genes and gene
arrangements. Our results do not yet establish the mech-
anism of gene expression of the two proteins. While we
have no data supporting the existence of two different
mRNAs, this cannot be formally ruled out at this stage.
This and the mode of translation initiation of NARR
are interesting open questions for the future.
Overlapping genes are made possible by the degeneracy
of the genetic code and are most common in viruses where
they are necessitated by the compactness of viral genomes.
It is also often observed in organisms with a limited
genome size (43). There are not many reports on the
protein products of mammalian overlapping genes, not-
withstanding the fact that a considerable fraction of mam-
malian genes is predicted to have overlaps (44). The most
well-known example of genuine protein products of
overlapping genes in humans is the case of mitochondrial
ATPase-6 and ATPase-8 subunits translated from the
same mRNA transcript and in the same direction
(although the mitochondrial genome is very different to
the nuclear genome) (45). Other examples include
Tenascin-X, the extracellular matrix protein encoded by
the gene overlapping P450c21B Steroid 21-hydroxylase
gene (46); the tumor suppressors ARF and p16 encoded
by overlapping genes transcribed in the same direction
(47); very-long-chain acyl-CoA dehydrogenase (VLCAD)
and discs-large-related 4 (DLG4) proteins whose
overlapping genes are transcribed in opposite directions
(48) and neuropeptide Y receptor subtypes Y1 and Y5
whose overlapping genes are also transcribed in opposite
directions (49). Despite these well-established examples,
the extent of overlap of various genomic sequence
messages, in particular in the genomes of higher eukary-
otes, is an open issue for evolutionary theoreticians, gen-
eticists and bioinformaticians.
Whereas different methods have been developed for
prediction of overlapping genes (44), so far, proteomics
methods using unassigned peptide/protein sequences
have hardly been employed for the experimental veriﬁca-
tion of products of such genes. Given the rapid evolution
of MS-based proteomics, we suggest that these methods
should now be used for detecting overlapping genes in a
systematic manner. The possibility of additional ‘protein
output’ of the same gene, with potentially different func-
tions to its conventional protein product raises interesting
functional questions that should be taken into account.
For example, when performing knock-down experiments
on rab34, our results suggest that one would have to
consider not only the effects of such a treatment with
regards to RAB34, a member of the Rab GTPase family
associated with the Golgi apparatus (50), but also on the
nucleolar protein NARR. While difﬁcult for the above
reasons, we believe that further research into NARR’s
intriguing link to rDNA clusters may provide interesting
clues about its roles in the nucleolar apparatus.
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